Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UCB Rocked By US FDA Rejection Of Blockbuster-In-Waiting Bimzelx

Agency Cites Facility Inspection Concerns With Psoriasis Filing

Executive Summary

The Belgian group’s US launch of Bimzelx could be delayed by up to a year after the FDA hit UCB with a complete response letter which states that "certain pre-approval inspection observations must be resolved” before the drug can get the green light for psoriasis.

You may also be interested in...



Keeping Track: US FDA Clears Vtama, But Not Bimekizumab Or Ycanth; Tibsovo Takes RTOR To Frontline AML Setting

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: a US setback for UCB; Lilly challenges Novo’s GLP franchise; Seagen searches for CEO after scandal; Hengrui hopes for US PD-1 success; and a look ahead at ASCO.

UCB’s Bimzelx Impresses In Psoriatic Arthritis Amid US Psoriasis Approval Delay

UCB’s Bimzelx has forged ahead with success in a late-stage psoriatic arthritis trial while it still awaits US approval for psoriasis, a hotly anticipated blockbuster indication.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146376

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel